Lepu Healthcare (300003): The 24Q1 business trend is positive and growth will resume throughout the year
Incident The company published its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 7.980 billion yuan (yoy -24.78%) and net profit to mother of 1,258 billion yuan (yoy-42.9 million yuan)
Lepu Healthcare (300003): 2024Q1 month-on-month improvement, optimistic that the company's innovative products will continue to reap
Key investment points: The 2023 performance fell short of expectations, and the 2024 month-on-month recovery: the company released the 2023 annual report. During the reporting period, it achieved operating income of 7.98 billion yuan, a year-on-year decrease of 25%; achieved net profit to mother of 12.58
Lepu Healthcare (300003): The 24Q1 business trend is improving, and innovative products are growing steadily
Lepu Healthcare announced its 2023 annual report. In 2023, the company achieved operating income of 7.980 billion yuan (year-on-year decrease of 24.78%); realized net profit to mother of 1,258 billion yuan (year-on-year decrease of 42.91%); actual
Revenue Miss: Lepu Medical Technology (Beijing) Co., Ltd. Fell 13% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
It's shaping up to be a tough period for Lepu Medical Technology (Beijing) Co., Ltd. (SZSE:300003), which a week ago released some disappointing quarterly results that could have a notable impact on h
Lepu Healthcare (300003): Overall performance is under pressure in the short term, optimistic that innovative businesses such as structural innovation will lead to a continuous recovery in performance
Event: The company released the 2023 annual report and the first quarter report of 2024. The full year of 2023 achieved operating income of 7.980 billion yuan (YoY -24.78%) and net profit of 1,258 billion yuan (YoY)
Lepu Healthcare (300003): Apparent performance is under pressure, optimistic that innovation will drive profit improvement
Event: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 7.980 billion yuan (-24.78%) and net profit to mother of 1,258 billion yuan (-42.91%),
Lepu Healthcare (300003): Performance continues to be under pressure, focus on subsequent marginal improvements
2023 and 1Q24 results fell short of our expectations The company announced full-year 2023 and 1Q24 results. 2023 revenue of $7.980 billion, -25% YoY, net of non-net profit of $1,123 million, YoY
Lepu Healthcare (300003): Month-on-month improvement in 1Q24, optimistic about the upward trend throughout the year
The company's 1Q24 performance showed a marginal improvement trend, maintaining that the “buy” rating company achieved revenue/net profit of 79.8/1.26 billion yuan (yoy -24.8%/-42.9%) in 23 years. We speculate that the main reason is domestic
Lepu Healthcare: Net profit for the first quarter was 481.9 million yuan.
Lepu Healthcare: Net profit for the first quarter was 481.9 million yuan.
Lepu Medical (300003.SZ): 0.53% of shares have been repurchased cumulatively
Gelonghui, April 3, 丨 Lepu Medical (300003.SZ) announced that as of March 29, 2024, the company had repurchased a total of 9,962,200 shares of the company's shares through a dedicated securities account, accounting for 0.53% of the company's latest total share capital. The highest transaction price was 16.65 yuan/share, the minimum transaction price was 12.18 yuan/share, and the total transaction amount was 149.304 million yuan (excluding transaction fees).
Express News | Lepu Medical: GLP-1/gcgr/GIP-FC fusion protein MWN101 completed the first phase II clinical trial
Lepu Healthcare: Further increasing the cash dividend ratio
Glonghui March 7 | Lepu Medical issued the “Notice on the Action Plan for Double Improvement of Quality and Return” on the evening of March 7. According to the announcement, the specific measures of the “Action Plan” include: 1. Deepening the main business and strengthening core competitiveness; 2. R&D and innovation to promote industry development; 3. Standardizing operations and improving the level of governance; 4. Strengthening trust and conveying corporate value; 5. Attaching importance to shareholders and strengthening return on investment. In the future, on the premise of ensuring the normal operation and long-term development of the company, the company will continue to pay attention to reasonable returns for investors, further increase the proportion of cash dividends, and allow shareholders to truly experience the company's development results.
Lepu Healthcare (300003.SZ): A total cost of 149.9 billion yuan to repurchase 9.622 million shares
Gelonghui, March 4, 丨 Lepu Medical (300003.SZ) announced that as of February 29, 2024, the company had repurchased 9.622 million shares of the company's shares through a dedicated securities account, accounting for 0.53% of the company's latest total share capital. The highest transaction price was 16.65 yuan/share, the minimum transaction price was 12.18 yuan/share, and the total transaction amount was 149.9 million yuan (excluding transaction fees).
Southwest Securities: There is still a lot of room for penetration in the coronary artery disease interventional treatment market, focus on Sano Healthcare (688108.SH), etc.
Coronary heart disease is the leading cause of death in the world, and there is still plenty of room for penetration in the interventional treatment market for coronary artery disease in China.
Lepu Medical (300003.SZ): Subsidiary companies intend to win the bid for clopidogrel bisulfate tablets, atorvastatin calcium tablets, and rosofastatin calcium tablets to win the bid for Guangdong Union Drug Collection
Gelonghui, Feb. 1, 丨 Lepu Medical (300003.SZ) announced that on January 31, 2024, the company learned that its subsidiaries Lepu Pharmaceutical Co., Ltd. and Lepu Pharmaceutical Technology Co., Ltd. participated in the bidding process for centralized volume procurement of drugs such as amoxicillin in Guangdong Union, and that they have passed the consistent evaluation of generic drug quality and efficacy, to win the bid for this centralized procurement. The above product companies all have their own raw materials.
Lepu Healthcare (300003.SZ): A total cost of 132 million yuan to buy back 8.5722 million shares
Gelonghui, February 1, 丨 Lepu Medical (300003.SZ) announced that as of January 31, 2024, the company had repurchased 8.572,200 shares of the company's shares through a dedicated securities account, accounting for 0.46% of the company's latest total share capital. The highest transaction price was 16.65 yuan/share, the minimum transaction price was 13.12 yuan/share, and the total transaction amount was 132 million yuan (excluding transaction fees).
Express News | Guo Tongjun, senior deputy general manager of Lepu Medical, received a warning letter from the Beijing Securities Regulatory Bureau when the securities account under his name traded in violation of regulations
Express News | Lepu Medical: Oseltamivir phosphate dry suspension received NMPA registration approval
Lepu Medical (300003.SZ): Coronary mastoid balloon dilatation catheter obtained NMPA registration approval
Gelonghui, January 22丨Lepu Medical (300003.SZ) announced today that the company's self-developed coronary mastoid balloon dilatation catheter was officially approved by the National Drug Administration (NMPA) and obtained a Class III medical device registration certificate. Registration certificate number: National Machinery Note 20243030105. The coronary mastoid balloon dilatation catheter is one of the important methods for dilating a narrow part of the coronary artery. Rows of mastoid processes are distributed on its surface. During high-pressure dilation, these mastoid processes can fracture hard plaques, and stay stably in the corresponding position during expansion to avoid sliding. After placing the stand
Lepu Medical (300003.SZ): A next-generation insulin plan has not yet been laid out
Gelonghui, January 22丨An investor asked Lepu Healthcare (300003.SZ) on the investor interactive platform, “Does the company currently have plans to develop next-generation insulin?” The company replied that the company has not yet laid out a next-generation insulin plan.
No Data